ArticleJournal of microscopy and ultrastructure
Structural and Biochemical Effects of Plumbagin on Sofosbuvir-induced Renal Cortical Injury in Rats: Role of Tumor Necrosis Factor-Alpha, Interleukin-6, JAK2/STAT3, and Nuclear Factor Kappa B-induced Inflammation.
Article in Journal of microscopy and ultrastructure. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatitis caused by virus C results in serious health complications. Sofosbuvir is effective for treating hepatitis C but, with side effects especially on kidneys. Plumbagin is a natural plant with a powerful anti-inflammatory effect. Aim: The assessment of plumbagin effect on the renal cortical damage in rats induced by sofosbuvir, by assessing tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), JAK2/STAT3 and nuclear factor kappa B (NF-κB). Materials and Methods: Forty adult rats (250-300 g) were divided into: group 1 (control); Group 2 received sofosbuvir 36 mg/kg; Group 3 received sofosbuvir and low dose of plumbagin (5 mg/kg); Group 4 received sofosbuvir and mid-dose of plumbagin (10 mg/kg); Group 5 received sofosbuvir and high dose of plumbagin (20 mg/kg); and Group 6 (sofosbuvir recovery). Drugs were taken once daily orally for 8 weeks. Blood samples were collected for the assessment of renal functions and serum TNF-α and IL-6. Renal specimens were processed for both measuring tissue JAK2/STAT3 levels and for histological and immunohistochemical studies. Results: Group 2 showed a significant rise of blood urea and serum creatinine, serum TNF-α and IL-6, tissue JAK2/STAT3, hematoxylin and eosin significant histopathological changes, significant increase of collagen area density at Masson's trichrome and significant rise of NF-κB-positive cells. Plumbagin treated groups showed dose-dependent amelioration of the preceding results. The recovery group showed partial recovery. Conclusion: Plumbagin has an ameliorating dose-dependent effect against sofosbuvir-induced renal cortical damage in rats rather than those left to recover alone through its antiinflammatory action. Hence, plumbagin could be promising for the treatment of different inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.